New insider activity at CG Oncology, Inc. ( (CGON) ) has taken place on September 4, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Hong Fang Song has recently sold 100,000 shares of CG Oncology, Inc. stock, amounting to a substantial transaction worth $2,779,542.
Recent Updates on CGON stock
CG Oncology, Inc. has recently completed enrollment in its Phase 3 PIVOT-006 study, which is a significant step in its clinical development for bladder cancer treatments. The company has been receiving positive attention from analysts, with Piper Sandler initiating coverage with an Overweight rating due to the potential for label extensions and multiple upcoming opportunities in the non-muscle invasive bladder cancer (NMIBC) space. Despite a slight decrease in the price target by BofA, the firm maintains a Buy rating, citing CG Oncology’s strong position in the HR NMIBC market and potential for significant value generation over the next 12-18 months. The company’s recent Q2 report highlighted clinical advancements and a favorable legal outcome, reinforcing its strategic position and future growth prospects.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc. has a moderate stock score driven by positive technical indicators and a stable financial foundation despite ongoing financial challenges. The lack of revenue and reliance on external funding are significant risks, but the stock’s current bullish momentum provides some optimism.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
YTD Price Performance: -1.04%
Average Trading Volume: 816,336
Technical Sentiment Signal: Buy
Current Market Cap: $2.09B